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1. Introduction 
Model systems are important tools for the investigation of pathogenic processes. Especially 
for diseases with a late onset of symptoms and slow progression, like most spinocerebellar 
ataxias (SCA), it is time-consuming or even impossible to analyze all aspects of the 
pathogenesis in humans. Due to the reduced lifespan of model organisms, it is possible to 
study disease progression in full within a reasonable timeframe and due to the shorter 
generation time of most model organisms more individuals can be generated and analyzed, 
thereby strengthening the reliability of data via an increased number of replicates. Detailed 
studies of the histopathology can only be performed as endpoint analyses in humans, but 
with the help of an animal model, multiple time points can be analyzed throughout the 
course of the disease. In addition, model systems allow not only for the reduction of time 
from idea to results but also reduce the complexity due to their smaller genome sizes, less 
genes, nonredundant pathways, and a simpler nervous system. 
Before using a specific species to model a disease it is of interest to check whether the 
proteins affected in humans are conserved within the respective model organism in order to 
increase the probability that binding partners and other keyplayers, involved in the 
pathogenesis of this disease, are likewise conserved. For those SCA which are caused by 
polyglutamine (polyQ) expansions, the respective affected genes are conserved in most 
organisms used as models (Table 1). Especially the proteins affected in SCA2, SCA6 and 
SCA17 are conserved with high similarity down to even yeast. This is not surprising as the 
TATA-binding protein (affected in SCA17) or a subunit of a voltage-dependent calcium 
channel (affected in SCA6) are important proteins for cellular maintenance. Although polyQ 
repeats are comparatively frequent in drosophila (Alba et al., 2007), only the repeat region of 
the TATA-binding protein is conserved. For most other non-mammalian model organisms, 
the respective orthologues are smaller and the polyQ repeats itself or even including the 
whole surrounding domains are not conserved. For analyses of SCA, various model systems 
have been employed. From the worm (Caenorhabditis elegans) and the fly (Drosophila 
melanogaster) all the way to mammals, i.e. the mouse (Mus musculus), model systems have 
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made important contributions to the understanding of disease progression and will be 
important tools for the first line tests of potential treatment strategies.  
This review aims to sum up the model systems used for the investigation of SCA and 
especially focuses on the lessons learned from these models about the pathogenesis of SCA. 
We also compare commons and differences in the results obtained using these animal 
models and highlight the species-specific advantages and possible problems associated with 
the use of this species as a model organism. 
2. Lessons learned from non-mammalian models of SCA 
2.1 Lessons learned from worm models 
The nematode Caenorhabditis elegans is frequently used as a model organism, primarily 
because of its anatomic and biochemical simplicity as well as its genetic tractability. The 
worm genome encodes orthologues for about 65% of all known human disease genes. 
Moreover, it allows for easy and rapid establishment of transgenic lines, thus facilitating 
screening and characterization of human disease-causing mutations in vivo. Overall it is an 
often used model organism to analyze pathological features of neurodegenerative diseases 
(Huntington’s disease, Parkinson’s disease or Alzheimer’s disease) (reviewed in Driscoll 
and Gerstbrein, 2003 and Brignull et al., 2006b). Except for ataxin-7, the worm contains 
orthologues for all SCA caused by polyQ expansion. Interestingly, for SCA C. elegans strains 
have only been generated and characterized for SCA2 and SCA3 (Ciosk et al., 2004; Khan et 
al., 2006; Kiehl et al., 2000; Rodrigues et al., 2007; Teixeira-Castro et al., 2011).  
In the field of polyQ diseases (e.g. HD or SCA) the formation of aggregates, and therefore, 
the transition of polyQ proteins to their toxic forms is not well understood. Due to its 
transparency, C. elegans is especially suitable to address this question. PolyQ proteins can be 
attached to a fluorescent protein (e.g. GFP, YFP, CFP) and the dynamics of aggregate 
formation both within individual cells and over time can be examined throughout the worm 
lifespan. Transgenic lines can be rapidly generated by feeding C. elegans wildtype strains 
with genetically transformed bacteria or by microinjection of manipulated DNA into the 
germline. The worm’s life-cycle of about 2 to 3 weeks under suitable living conditions is 
short. This allows studying the aggregate formation of many different constructs with 
various polyQ lengths, with or without flanking sequences of the endogenous protein and 
under control of a wide range of different promoters. When expressed in the body wall 
muscle of C. elegans, even short polyQ stretches (with less than 40 Qs) without any flanking 
sequences from endogenous proteins tend to aggregate in old worms indicating a balance of 
different factors including repeat length and changes in the cellular protein-folding 
environment over time (Morley et al., 2002). In neurons, however, the pathogenic threshold 
turned out to be about 35-40 repeats, which correlates well with the human disease. This 
means that in comparison with muscle cells, neuronal cells have a higher aggregation 
threshold (Brignull et al., 2006a). By way of contrast, the analysis of aggregation in the 
protein context of (full-length) ataxin-3 revealed that only a highly expanded polyQ stretch 
(Q130) was able to induce the formation of aggregates in the cytoplasm and nucleus of 
neuronal cells in transgenic C. elegans lines. Non-expanded (Q14, Q17) and even pathological 
expanded polyQ stretches (Q75, Q91) were diffusely distributed within neurons  
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without aggregation (Khan et al., 2006; Teixeira-Castro et al., 2011). In a truncated protein of 
ataxin-3, however, just 63Q are sufficient for aggregation mainly in the perinuclear region 
but rarely in the nucleus (Khan et al., 2006). These results are in line with observations made 
in mouse models, where a truncated form of the polyQ expanded protein induced more 
aggregates and a more progressive neurological phenotype than the full-length protein 
(Ikeda et al., 1996).  
C. elegans is also a useful organism for studying the normal distribution and function of 
polyQ proteins both during development and throughout the full lifespan. For example, a 
SCA2 transgenic model, which expressed the C. elegans orthologue of the human ataxin-2 
gene under the control of the endogenous promoter, revealed a strong expression of ataxin-2 
in the central nervous system of adult worm, but also allowed the detection of ataxin-2 even 
in the early embryo, beginning around the 4-cell stage (Kiehl et al., 2000). Likewise, the 
expression of the worm orthologue of the human ataxin-3 was strongly detected during the 
late embryogenesis and during all stages of postnatal development. Interestingly, ataxin-3 
was not only detected in the central nervous system (in the neuronal dorsal and ventral cord 
as well as in neurons of the head and tail) but was also observed in the spermatheca, vulval 
muscle, hypoderm, coelomocytes and body muscles (Rodrigues et al., 2007).  
Using knock-out strains or knocking down expression of polyQ proteins with a siRNA 
loaded diet has provided another method for the study of polyQ distribution and function. 
The knockdown of ataxin-2 by siRNA results in reduced numbers of eggs and 
developmental arrest whereas the knock-out of this gene was embryonically lethal (Kiehl et 
al., 2000). In comparison, the knock-out of ataxin-3 results in viable animals, which show no 
obvious morphological abnormalities as well as normal lifespan and behaviour (Rodrigues 
et al., 2007) but a significantly increased resistance to stress (Rodrigues et al., 2011).        
Aside from protein distribution C. elegans has been used to study synaptic function (Khan et 
al., 2006) and to perform genome-wide RNAi-based genetic screens to identify modifiers 
(Poole et al., 2011). Such a RNAi screen identified that the aggregation of pure polyQ repeats 
was enhanced by factors involved in RNA metabolism and protein synthesis (leading to an 
increased production of misfolded proteins) as well as factors involved in protein folding, 
transport and degradation (leading to decreased protein clearance) (Nollen et al., 2004). 
Invertebrate models, like C. elegans, are also particularly useful models for first-line 
screenings of possible therapeutic compounds, especially in late-onset neurodegenerative 
diseases such as SCA. The useful nature of C. elegans in such screenings was demonstrated 
in 2007 when a first drug screening for Huntington’s disease was published. Voisine et al. 
developed a so called food clearance assay by exploiting that C. elegans can easily be 
cultured in solution. For this assay, wildtype C. elegans were incubated in E. coli liquid 
culture to determine the optimal drug concentration. The optical density was used to 
measure the consumption of E. coli (food source) to indicate the growth or survival of C. 
elegans. Drugs in the established concentrations were then used to treat worms with a polyQ 
expanded huntingtin (Htn-Q150) and analyzed using a starvation assay (by measuring the 
presence or absence of GFP expression in neurons). In this assay, a HDAC inhibitor 
(Trichostatin, TSA) was able to suppress neurodegeneration and LiCl decreased polyQ-
induced neurodegeneration, while NaCl had no effect (Voisine et al., 2007).   
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Although no single model organism is able to recapitulate all features of a human disease, C. 
elegans models have proven to be a very good starting point. Worm models allow answering 
research relevant questions in vivo in an easy to handle and “low-cost” organism, before 
generating a more complex and expensive, but also more comparable model to human 
diseases, like mouse models. 
2.2 Lessons learned from fly models 
A big advantage of disease models involving Drosophila melanogaster is the so called GAL4-
UAS system (Brand and Perrimon, 1993; Fischer et al., 1988). A specific promoter controls 
the expression of the transcription factor GAL4 which binds the UAS (upstream activating 
sequence) in the responder construct containing the gene of interest. The use of different 
promoter GAL4-lines, thereby, allows controlling the expression strength and/or directing 
the expression of the disease–causing gene to different organs or cell types. A frequently 
chosen promoter is the mainly eye specific gmr-GAL4 driver (Freeman, 1996) directing the 
transgene to the flies eyes. Drosophila eyes are highly organized structures thereby allowing 
a macroscopic observation of the degeneration of (visual) neurons without the need of even 
preparing and staining brain sections. The high reproducibility, the simple breeding and the 
ease of analyzing neurodegeneration macroscopically make Drosophila models the ideal tool 
for the screening for and analysis of factors influencing neurodegenerative events in SCA. 
However, not all genes causing SCA are conserved in flies, e.g. there are no natural 
orthologues for ataxin-3 and ataxin-7 in Drosophila melanogaster. However, the CACNA1A, 
the affected gene in SCA6, as well as ataxin-1 (Tsuda et al., 2005) and ataxin-2 seem to be 
conserved albeit with only reduced homology (Rubin et al., 2000) as the CAG repeat is 
missing in these genes. This lack of endogenous genes excludes any knock-in or knock-out 
approaches and at first sight questions the chance of successful generation of transgenic 
models for these diseases as relevant binding partners for the affected proteins may also not 
be conserved. Interestingly, the sole overexpression of the Drosophila orthologue of ataxin-1 
(dAtx-1) induced a similar phenotype than the overexpression of human ataxin-1 (hATXN1) 
although dAtx-1 misses more than 60 % of hATXN1 amino acids including the polyQ repeat 
(Tsuda et al., 2005). Not even a polyQ expansion is required as a high level of hATXN1 with 
normal repeat length (30Q) caused neuronal degeneration (Fernandez-Funez et al., 2000). 
This data indicates that both Drosophila and human ataxin-1 are “intrinsically toxic at high 
levels” (Lu and Vogel, 2009). Likewise, the overexpression of dAtx2, the Drosophila 
orthologue of human ataxin-2, caused developmental defects and degeneration of tissues 
(Satterfield et al., 2002). As well the loss of dAtx2 had comparable effects, stressing the 
importance of maintaining normal ataxin-2 activity (Satterfield et al., 2002).  
Analyses using Drosophila connected pathogenic mechanisms in SCA1, SCA2, and SCA3 and 
identified ataxin-2 as a potential key player both in SCA1 and SCA3 (Al-Ramahi et al., 2007; 
Lessing and Bonini, 2008): In both cases, the overexpression of dAtx2 enhanced the 
neurodegeneration caused by ataxin-1 and ataxin-3, respectively, and downregulation of 
dAtx2 had the opposite effect. Comparable observations were made even for a non-polyQ 
disease, amyotrophic lateral sclerosis (ALS) (Bonini and Gitler, 2011). This influence of dAtx2 
seems to be linked to the conserved PAM2 motif (PABP-interacting motif 2) within ataxin-2 
which mediates the interaction of ataxin-2 with the Poly(A)-binding protein (PABP) (Lessing 
and Bonini, 2008) implicating ataxin-2 in the regulation of translation of specific mRNAs 
(Satterfield and Pallanck, 2006). The general importance of protein domains apart from the 
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polyQ repeat were first addressed using pure polyQ repeats which proved to be toxic in 
Drosophila in expanded, but not in normal lengths (Marsh et al., 2000). However, adding as 
few as 26 additional amino acids (such as addition of a myc and a FLAG tag) and even 
more, adding the surrounding amino acids of a full protein is able to even neutralize the 
toxic effect of expanded polyQ repeats (Marsh et al., 2000).  
Drosophila models were also used to assess the relevance of the intracellular localization of 
the affected protein: Ataxin-2 is normally a cytoplasmic protein and the occurrence of 
intranuclear aggregates in SCA2 patients is still controversial as both the presence and 
absence of nuclear aggregates have been described (Huynh et al., 2000; Koyano et al., 2000). 
However, the intracellular localization of dAtx2 strongly influences the phenotype in flies. 
While nuclear dAtx2 induces strong neurodegeneration, the phenotype of flies with 
cytoplasmic dAtx2 is much milder (Al-Ramahi et al., 2007).  
As SCA are neurodegenerative disorders, with ubiquitous expression of the disease causing 
gene in humans, glial cells are usually not the main focus of interest. However the choice of 
different driver lines allows for the analysis of glial vs. neuronal expression of the disease-
causing genes in Drosophila. Data suggest that the effect of glial expression of the transgene 
is more pronounced than of neuronal expression (Kretzschmar et al., 2005). 
Another strong advantage of Drosophila as a model organism is the suitability for large-scale 
screens for modifying factors. Such screens for ataxin-1, ataxin-3 or even pure polyQ repeats 
identified somehow expected proteins involved in protein folding (like chaperones) and 
protein degradation (components of the ubiquitin-proteasome system and autophagy) (Bilen 
and Bonini, 2007; Fernandez-Funez et al., 2000; Kazemi-Esfarjani and Benzer, 2000; Latouche et 
al., 2007). In addition, these screens gave insight into further mechanisms relevant for polyQ 
disease pathogenesis like cellular detoxification, protein transport, transcriptional regulation 
and RNA and miRNA processing (Bilen and Bonini, 2007; Bilen et al., 2006; Fernandez-Funez 
et al., 2000; Latouche et al., 2007). The identification of muscleblind (mbl) as a modifier of an 
SCA3 fly model drew attention to the role of CAG repeat RNA in the pathogenesis of SCA3 (Li 
et al., 2008) and led to the conclusion that not only the expanded polyQ repeat but also the 
RNA coding for it has an effect on the pathogenesis of polyQ diseases at least in Drosophila. 
Muscleblind is known to be involved in Myotonic dystrophy caused by aberrant RNA 
containing massive CUG expansions (Jiang et al., 2004). The expression of an untranslated 
CAG repeat caused neurodegeneration in Drosophila. This toxicity was mitigated just by the 
interruption of the pure CAG repeat by replacing it with a CAACAG repeat (Li et al., 2008). 
These results were in line with previous data for a non-polyQ SCA, SCA8, also caused by non-
coding RNA. Both a normal and an expanded CAG repeat led to neurodegeneration in a fly 
model of SCA8 (Mutsuddi et al., 2004). Interestingly, a screen for modifiers of this phenotype 
caused by non-coding RNA (containing expanded CAG repeats) pointed to several pathways 
which were also identified as modifiers of a phenotype caused by (translated RNA coding for) 
expanded polyQ repeats (Mutsuddi et al., 2004). Taken together, disease models in Drosophila 
facilitated both the identification and further analysis of multiple factors and mechanisms 
involved in the pathogenesis of SCA. 
3. Lessons learned from mammalian models of SCA 
In contrast to disease models in the worm or the fly, mouse models resemble pathogenic 
processes in humans much closer than their non-mammalian counterparts. For example the 
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brain structure of mice is much closer to that of humans than those of flies or worms and 
mechanisms of special importance for late-onset diseases like SCA, e.g. gene expression 
changes during aging (Bishop et al., 2010), are better conserved. In particular, mouse models 
allow analyzing aspects of the disease which cannot be analyzed in simpler organisms. 
Although behavioural analyses are possible in C. elegans and Drosophila models, they are 
rather basic compared to more sophisticated behavioural tests possible with mouse models 
which even allow for e.g. fear and spatial learning analyses (Huynh et al., 2009). 
3.1 Lessons learned from knock-out mouse models 
In mouse models, it is possible to selectively inactivate a specific gene-of-interest via gene 
targeting. There is a large amount of insight to be gained from generating such knock-out 
models and a lot of information has been uncovered about the functional roles of specific 
genes in mammalian biology (Capecchi, 2005). To learn about the native function of genes 
affected in SCA knock-out mice were generated for SCA1, 2 and 3. All mice were viable, 
fertile and had a normal lifespan with no severe ataxic phenotype or neurodegeneration 
(SCA1: Matilla et al., 1998; SCA2: Kiehl et al., 2006; Lastres-Becker et al., 2008; SCA3: Schmitt 
et al., 2007; Switonski et al., 2011), providing evidence that loss-of-function is not the 
primary cause for ataxic symptoms in these disorders. However, these mice served to give 
indications for normal functions of the respective knock-out genes. For ataxin-1, the gene 
affected in SCA1, a role in learning and memory was identified (Matilla et al., 1998) and its 
function as a transcriptional co-regulator was elucidated (Goold et al., 2007). Knocking out 
the ataxin-2 gene led to adult-onset obesity and reduced fertility (Kiehl et al., 2006; Lastres-
Becker et al., 2008a) as well as hyperactivity and abnormal fear-related behaviour (Huynh et 
al., 2009). In ataxin-3 knock-out mice increased levels of ubiquitinated proteins were 
detected reflecting its function as a deubiquitinating enzyme (Schmitt et al., 2007). However, 
in a second SCA3 knock-out model changes in the ubiquitination level were not observed. 
The authors suggested compensational effects as the cause for this opposing result 
(Switonski et al., 2011). Other analyses on SCA3 knock-out mice were able to show a 
protective function of ataxin-3 in the heat shock response pathway (Reina et al., 2010).  
In contrast to only mild effects observed with the deletion of genes responsible for polyQ 
products, the knock-out of genes affected in non-polyQ SCA resulted in severe ataxic 
phenotypes. The deletion of the Klhl1 gene which is mutated in SCA8 led to the loss of 
motor coordination due to degeneration of Purkinje cell function (He et al., 2006). The 
analysis of mice showing signs of a severe autosomal recessive movement disorder revealed 
a deletion in the inositol 1,4,5-triphosphate receptor (ITPR1 gene) as the cause of the 
observed symptoms. Knowing that the gene correlated to SCA15 in humans maps to the 
ITPR1 genomical region, it was possible to identify a deletion in this gene as the cause of this 
autosomal dominant disorder (van de Leemput et al., 2007).  
Taken together, the analyses of SCA knock-out mice demonstrated a toxic gain-of-function 
as the cause for SCA due to polyQ expansions, whereas for non-polyQ SCA loss-of-function 
seems to be the primary mechanism of pathogenesis.   
3.2 Lessons learned from classical transgenic mouse models for SCA 
Transgenic mouse models gave insight into various pathogenic mechanisms in SCA. Here, 
we review three examples: Lessons learned about the cell-type specificity of neuro-
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degeneration, the aggregation and localization of the affected protein as well as 
transcriptional dysregulation caused by expanded polyQ proteins.  
3.2.1 Lessons learned about the cell-type specificity of neurodegeneration 
A classical transgenic mouse model is generated by using a specific promoter typically 
controlling the expression of a cDNA construct of the respective gene-of-interest. The effect 
of expressing different transgenes in a specific subgroup of neurons can be nicely compared 
among several proteins affected in SCA as the Purkinje-cell-specific promoter (Pcp2/L7 
promoter) (Vandaele et al., 1991) was used for the generation of transgenic mice for SCA1 
(Burright et al., 1995), SCA2 (Huynh et al., 2000), SCA3 (Ikeda et al., 1996), SCA7 (Yvert et 
al., 2000) and SCA17 (Chang et al., 2011), respectively. In the SCA1, SCA2 and SCA17 mouse 
models the expanded full-length transgene causes a strong degeneration of Purkinje cells 
(Burright et al., 1995; Chang et al., 2011; Huynh et al., 2000). By contrast, in the SCA7 mouse 
model, the sole expression of full-length ataxin-7 with 90 Q induced a behavioural 
phenotype, but only mild degeneration of Purkinje cells in quite old mice (Yvert et al., 2000). 
Ironically, the expression of full-length ataxin-7 (92 Q) in most neurons except for Purkinje 
cells (Garden et al., 2002; La Spada et al., 2001) or even just in Bergmann glia cells (Custer et 
al., 2006), led to a strong degeneration of Purkinje cells (Custer et al., 2006). Likewise, when 
a full-length ataxin-3 protein with 79 Q was expressed using the same promoter, no 
phenotype was induced. Only a fragment containing not more than a few amino acids 
surrounding the expanded polyQ repeat was able to induce a phenotype (Ikeda et al., 1996). 
These data demonstrate that Purkinje cells in transgenic mice seem to be more vulnerable by 
a repeat expansion within ataxin-1, ataxin-2 and ataxin-17, than by an expansion within 
ataxin-3 and ataxin-7, thereby –at first sight- nicely replicating the situation in humans where 
Purkinje cells are strongly affected in SCA1 (Cummings et al., 1999a), SCA2 (Lastres-Becker 
et al., 2008b) and SCA17 (Rolfs et al., 2003), but the loss of Purkinje cells can be observed but 
is not so prominent in SCA3 patients (Rüb et al., 2002a; Rüb et al., 2002b). In SCA7, however, 
Purkinje cells are typically affected (Holmberg et al., 1998), thereby possibly indicating that 
the pathogenic processes leading to Purkinje cell death in SCA7 differ from those in SCA1, 
SCA2 and SCA17. 
3.2.2 Lessons learned about the aggregation of polyQ proteins and their localization 
A common feature of polyQ as well as other neurodegenerative diseases is the accumulation 
of insoluble proteins in neurons, a feature recapitulated by most model systems of these 
disorders. Despite this fact the role of these so called neuronal nuclear inclusions (NIIs) in 
the pathological processes of polyQ diseases is still controversially discussed but it is known 
that these structures are associated with pathogenesis. Analysis of a C. elegans model of 
SCA3 directly linked the formation of aggregates to neuronal dysfunction (Teixeira-Castro 
et al., 2011), whereas several opposing results in mouse models exist. Observations in 
transgenic mouse models for SCA1, SCA2, SCA3 and SCA6 (Boy et al., 2010; Cummings et 
al., 1999b; Huynh et al., 2000; Klement et al., 1998; Silva-Fernandes et al., 2010; Watase et al., 
2008) reveal that the development of a pathological phenotype is independent of the 
formation of inclusions excluding large aggregates as a primary cause for neuronal 
dysfunction. Even more, evidence exists for a protective role of inclusion bodies (Bowman et 
al., 2005). Inclusions in human SCA patients and respective mouse models stain positive for 
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ubiquitin and other components of the ubiquitin-proteasome-system (UPS) (Bichelmeier et 
al., 2007; Cummings et al., 1998; Holmberg et al., 1998; Klement et al., 1998; Koyano et al., 
1999; Paulson et al., 1997; Schmidt et al., 2002; Watase et al., 2002; Yvert et al., 2000) pointing 
to an involvement of this protein degradation system in the clearance of proteins with 
expanded CAG repeats. In C. elegans it was observed that expanded polyQ tracts impair the 
functions of UPS (Khan et al., 2006). In brains of SCA3 patients a marked misdistribution of 
proteasomal subunits was detected leaving only a subpopulation of neurons with the 
possibility to form functional proteasome complexes (Schmidt et al., 2002). Comparable 
results were obtained for SCA1 patients and transgenic mice (Cummings et al., 1998) and 
further studies revealed that an impairment or altered function of the ubiquitin and the 
proteasomal degradation system could contribute to the SCA1 pathogenesis (Cummings et 
al., 1999b; Hong et al., 2002). Data gained using a knock-in model, though, excluded an 
impairment of the ubiquitin-proteasome-system as a major neuropathological cause of SCA7 
(Bowman et al., 2005). 
The mechanism which leads to the formation of aggregates is not well understood. It has 
been proposed that proteolytic cleavage of polyQ-containing proteins is required for 
aggregate formation, because polyQ-containing fragments are predominantly found in NIIs. 
Another indication for the cleavage hypotheses is the detection of protein fragments in 
brains of mouse models for SCA3 (Goti et al., 2004), SCA7 (Garden et al., 2002) and SCA17 
(Friedman et al., 2008) as well as human SCA patients (Garden et al., 2002; Goti et al., 2004). 
As possible protein cleavage enzymes, caspases or calpains are under controversial 
discussion. For ataxin-3, calpain (Haacke et al., 2007; Koch et al., 2011) and caspase cleavage 
was analyzed in vitro (Berke et al., 2004; Pozzi et al., 2008). It was shown that a C-terminal 
fragment of ataxin-3 containing the polyQ stretch leads to a more progressive phenotype 
(Ikeda et al., 1996), but also an N-terminal fragment without the CAG repeats can cause 
SCA3 symptoms (Hübener et al., 2011). In addition, mice expressing a fragment of the 
TATA-binding protein (affected in SCA17) exhibit a more severe phenotype (Friedman et 
al., 2008) than those expressing a full-length protein (Friedman et al., 2007). These studies 
suggest that cleavage of the affected protein is important for the pathogeneses of polyQ 
SCA. Although neuronal nuclear inclusions (NIIs) are a common feature of polyQ diseases, 
in some SCA the affected protein is normally localized in the cytoplasm. For this reason, the 
question arose whether the intracellular localization of the affected protein is of relevance 
for the pathogenesis of SCA. For an polyQ expansion within an ectopic protein context 
(Jackson et al., 2003), for ataxin-1 (Klement et al., 1998) and for ataxin-3 (Bichelmeier et al., 
2007) it was demonstrated that the nuclear localization of the affected protein is a 
requirement for the manifestation of symptoms. Mice in which the respective protein was 
kept in the cytoplasm typically had less and smaller aggregates and milder or even almost 
no behavioural phenotype. For SCA1, Emamian et al. (2003) even went one step further 
demonstrating that although the nuclear localization of ataxin-1 is required, it is not 
sufficient to induce a phenotype. A serine residue close to the endogenous NLS within 
ataxin-1 (S776) was required additionally for the induction of a phenotype (Emamian et al., 
2003). 
3.2.3 Lessons learned about transcription dysregulation 
Transcriptional dysregulation is a common feature of most polyQ diseases, but the 
underlying mechanisms which cause the differential regulation remain unknown. Many 
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proteins affected in polyQ diseases are functioning as transcription factors/cofactors or at 
least interact with transcription factors: TBP (SCA17) is a general transcription factor, ataxin-
7 is a part of a transcriptional co-activator complex and both ataxin-1 and ataxin-3 interact 
with various transcription factors (Helmlinger et al., 2006). 
Especially for SCA1, the molecular basis of transcriptional dysregulation and therefore its 
influence on the pathogenesis is thoroughly studied. Transcriptional dysregulation 
mediated by ataxin-1 has been attributed to the interaction with the polyQ binding protein 1 
(PQBP1). This interaction interferes with the cellular RNA polymerase-dependent 
transcription (Okazawa et al., 2002). Microarray analyses of SCA1 knock-in and knock-out 
mice revealed differential expression of proteins involved in calcium signaling (Crespo-
Barreto et al., 2010). In SCA3 and SCA7, components of the NIIs are transcriptionally 
dysregulated, including subunits of the proteasome and heat shock proteins (Chou et al., 
2010; Chou et al., 2008). Several other transcription factors such as CREB (cAMP response 
element binding protein) and HDAC proteins and therefore histone deacetylation is often 
differential regulated in polyQ diseases (McCampbell et al., 2000; McCullough and Grant, 
2010). For this reason, treatment studies using HDAC inhibitors such as sodium butyrate 
were performed (Chou et al., 2011; McCampbell et al., 2001). In several studies, 
transcriptional dysregulation is associated with the degeneration of specific neurons: for 
SCA17, a downregulation of TrkA (nerve growth factor receptor) is linked to Purkinje cell 
degeneration (Shah et al., 2009), or for SCA1 an interaction of ataxin-1 and PQBP1 and 
therefore transcriptional dysregulation leads to selective neuronal loss in the cerebellum 
(Okazawa et al., 2002). 
3.3 Lessons learned from YAC, BAC and knock-In mouse models 
In the process of generating classical transgenic mice it is only possible to insert cDNA 
randomly into the animal genome, not allowing for controlling the expression of the 
pathogenic gene in the native genetic environment at endogenous levels or excluding 
alternative splicing events. Therefore, different techniques have been developed to 
overcome these limitations and to generate models which more closely resemble human 
disease conditions. One strategy was the use of a yeast artificial chromosome (YAC) 
containing a large fragment of the human MJD1 locus for the generation of a model for 
SCA3 thus enabling the expression of a full-length ataxin-3 gene with the endogenous 
regulatory elements needed for cell specificity and endogenous levels of expression (Cemal 
et al., 2002). Mice with expanded CAG tracts showed mild and slowly progressing cerebellar 
symptoms with nuclear inclusions and cell loss in specific brain regions closely resembling 
main features of the SCA3 disease in humans (Cemal et al., 2002). A likewise approach was 
used to generate a model for SCA8. Moseley et al. (2006) used a bacterial artificial 
chromosome (BAC) to control the expression of the SCA8 locus encoding a non-expressed 
transgene. If they would have used just a classical transgenic construct without 116 kb of 
flanking sequences they may not have observed that the construct is indeed expressed in 
both directions encoding both a non-translated RNA containing a CTG expansion as well as 
a polyQ containing protein expressed from the opposite strand (Moseley et al., 2006). 
A different more widely used strategy in the generation of SCA mouse models is to take 
advantage of homologous recombination techniques leading to knock-in models. This 
allows for endogenous levels of expression in proper spatio-temporal patterns (Yoo et al., 
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2003). The first knock-in model generated for SCA1 targeted an expanded CAG tract of 78 
repeats to the endogenous ataxin-1 mouse locus. These mice reflected genetic repeat 
instability observed in human SCA1 patients, but showed only mild behavioural changes in 
late life with no clear neuropathological changes (Lorenzetti et al., 2000). From this first 
attempt the conclusion was drawn that the short lifespan of mice seems to be a limiting 
factor and that the longer exposure of the mutant protein in humans might be necessary for 
the development of neuronal dysfunctions. This drawback can be overcome by either 
overexpression of mutant proteins or by the use of extremely long CAG tracts to produce 
neurodegeneration (Yoo et al., 2003; Zoghbi and Botas, 2002). Therefore, in the next knock-in 
model for SCA1, more CAG repeats (154 repeats) were used and this model then indeed 
resembled main features of the human SCA1 disease (Watase et al., 2002). Analyzing these 
mice it was also shown that there is no direct relationship between the degree of somatic 
instability and the selective neuronal toxicity (Watase et al., 2003), but that the selective 
neuropathology rather arises from alterations in the function of the ataxin-1 protein 
(Bowman et al., 2007). Furthermore, these mice served to demonstrate that a partial loss-of-
function contributes to the SCA1 pathogenesis (Bowman et al., 2007; Crespo-Barreto et al., 
2010; Lim et al., 2008). SCA6 knock-in mice with up to 84 (hyperexpanded) CAG repeats in 
the CACNA1A gene (encoding for a calcium channel subunit) gave evidence against the 
assumption that the SCA6 pathogenesis is caused by alterations of channel properties and 
rather indicated that it is due to the accumulation of mutant calcium channels (Saegusa et 
al., 2007; Watase et al., 2008). In infantile cases of SCA7 expansions of 200-460 CAG repeats 
were documented (Benton et al., 1998; van de Warrenburg et al., 2001) and knock-in mice 
with 266 CAG repeats indeed reproduced hallmark features of the infantile disease (Yoo et 
al., 2003). Using this knock-in model it was shown that polyQ nuclear inclusions seem to 
have a protective role against neuronal dysfunction, that an impairment of the ubiquitin-
proteasome-system can be excluded as a major neuropathological cause (Bowman et al., 
2005) and that SUMOylation influences the aggregation process of ataxin-7 (Janer et al., 
2010). A most recent publication reported on the attempt to generate the first knock-in 
mouse model of SCA3, but due to unexpected splicing events ended up creating another 
SCA3 knock-out model (Switonski et al., 2011) showing some of the difficulties which may 
occur generating animal models.  
3.4 Lessons learned from an alternative strategy to generate mouse models 
An alternative approach for the generation of animal models is the use of viral injections. By 
using lentiviral vectors it was possible to overexpress wildtype or polyQ expanded ataxin-3 
in brain regions of adult wildtype rats. An expression of polyQ-expanded ataxin-3 in the 
substantia nigra, an area affected in SCA3, led to the formation of ubiquitinated ataxin-3 
positive aggregates, loss of dopaminergic markers and an apomorphine-induced turning 
behaviour. If polyQ expanded ataxin-3 is overexpressed in the striatum or cortex, regions 
previously not linked to SCA3 pathogenesis, by the lentiviral-based system it results in 
accumulation of misfolded ataxin-3 and loss of neuronal markers especially in the striatum 
(Alves et al., 2008b). Using the lentiviral vector system it is also possible to co-express 
ataxin-3 with knock-down vectors or other proteins and to analyze direct effects in specific 
brain regions. For example a co-expression of expanded ataxin-3 with beclin, an autophagic 
protein, led to stimulation of autophagic flux, clearance of mutant ataxin-3 and 
neuroprotective effects (Nascimento-Ferreira et al., 2011).  
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3.5 Treatment approaches using mouse models 
At the moment, curative treatment for SCA is not possible. Only treatments directed 
towards alleviating symptoms are available (Duenas et al., 2006).  Therefore, one or the most 
important goal in the research of SCA is the development of a cure.  
The basic question of whether any treatment -if available- would be able to even reverse 
symptoms already manifested was addressed using conditional mouse models. With these 
models which allow to turn off the pathogenic trangene expression using the Tet-off system 
it was possible to demonstrate that already developed symptoms of SCA1 and SCA3 indeed 
can be reversed (Boy et al., 2009; Zu et al., 2004). Inhibiting or reducing the production of 
pathogenic proteins could therefore be a powerful tool in the therapy of dominant 
neurodegenerative diseases. Using the RNA interference (RNAi) technology (Mello and 
Conte, 2004) to inhibit the expression of mutant ataxin-1 in a mouse model of SCA1 led to 
improved motor coordination, restored cerebellar morphology as well as resolved ataxin-1 
inclusions demonstrating the in vivo potential of this strategy (Xia et al., 2004). RNAi 
knockdown was also successfully used for a selective allele-specific silencing of mutant 
ataxin-3 showing to mitigate neuropathological abnormalities in a lentiviral-mediated 
model of SCA3 (Alves et al., 2008a; Alves et al., 2010) and may be a possible treatment 
approach. As protein misfolding and impaired protein degradation is implicated in the 
pathogenesis of polyQ SCA and other related diseases that present with intracellular 
inclusion bodies, supporting the correction of these alterations might be a therapeutic 
strategy. In this manner it was possible to show that crossbreeding of SCA1 transgenic mice 
with mice overexpressing a molecular chaperone leads to the mitigation of the SCA1 
phenotype (Cummings et al., 2001). 
In addition to genetic approaches, some of the published mouse models have already been 
used to test the effect of different compounds on the movement phenotype, neuronal loss 
and aggregate formation: Lithium carbonate enhanced the motor performances and 
improved spatial learning, but had neither an effect on the distribution and formation of 
aggregates nor did it improve the lifespan of the SCA1 knock-in mice (Watase et al., 2007). A 
treatment approach using lithium chloride in a C. elegans model for Huntington’s disease, 
however, was beneficial (Voisine et al., 2007). A dietary supplementation with creatine 
improved survival and motor performance and delays neuronal atrophy in the R6/2 
transgenic mouse model of Huntington's disease. In a SCA2 transgenic mouse model, 
however, creatine extended the Purkinje cell survival, but was not able to improve or delay 
ataxic symptoms (Kaemmerer et al., 2001). Two promising studies were performed using 
transgenic models for SCA3: The HDAC inhibitor sodium butyrate (SB) delayed the onset of 
ataxic symptoms and improved the survival rate by reversing polyQ induced histone 
hypoacetylation and transcriptional repression (Chou et al., 2011). In addition, a rapamycin 
ester (also called temsirolimus or CCI-779) which inhibits the mammalian target of 
rapamycin and upregulates the protein degradation by autophagy, reduced the number of 
aggregates and improved the motor performance (Menzies et al., 2010). In a study using a 
SCA2 mouse model, the Ca2+ stabilizer dantrolene was able both to alleviate motor 
symptoms and to reduce the loss of Purkinje cells in this model (Liu et al., 2009). Another 
group used a specific mouse model, the so called rolling mouse Nagoya, which has been 
suggested as an animal model for some human neurological diseases such as autosomal 
dominant cerebellar ataxia (SCA6). This model was treated with talrelin, a synthetic 
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analogue of the thyrotropin-releasing hormone (TRH) which alters the metabolism of 
acetylcholine and dopamine and therefore activates the dopaminergic system. Talrelin 
significantly elevated the cerebellar dopamine and serotonin levels of mice and improved 
the locomotion phenotype (Nakamura et al., 2005).  
Other therapeutical attempts are based on the functional restoration of affected cell 
populations. Expanded ataxin-1 causes the degeneration of Purkinje cells thereby also 
negatively effects the synthesis of the insulin-like growth factor–I (IGF-I) a factor promoting 
Purkinje cell development (Fukudome et al., 2003). Administering this factor to SCA1 
transgenic mice (SCA1[82Q]) intranasally led to significant improvement of motor 
coordinative abilities as well as to partial restoration of Purkinje cell survival (Vig et al., 
2006). Using the same SCA1 transgenic model, improved motor skills and a higher Purkinje 
cell survival rate was reached after grafting neural precursor cells into the cerebellar white 
matter (Chintawar et al., 2009). Although there is a long way from successful treatment 
approaches in animal models to clinical application, the recent results give hope that 
treatment of SCA will be possible in the future. 
4. Commons and differences between SCA models in worms, flies and mice 
It is self-evident that the data acquired in different model organisms especially those 
obtained in non-vertebrate compared with those from vertebrate models cannot be identical. 
However, if results obtained in a specific model are to be translated to the situation in 
humans one would expect that basic mechanisms in the pathogenesis of SCA are conserved 
among species. Previous studies revealed that many pathogenic mechanisms are indeed 
comparable among species, however, also indicated that there are some differences between 
model organisms (Table 2). Orthologues of ataxin-2 can be found all the way down to 
simple organisms and even in yeast (Table 1). However, the knock-out of ataxin-2 gave rise 
to contradictory results among model organisms: The knock-out of the endogenous SCA2 
gene in the worm and the fly is embryonic lethal. In contrast to that, SCA2 knock-out mice 
are viable and showed no developmental defects. Further analyses of SCA2 knock-out 
worms demonstrated that ataxin-2 is functioning during development, since the knockdown 
by RNAi results in developmental arrest. 
These results indicate that the function of homologous proteins as well as the interaction of 
different proteins in special pathways is not conserved in the species analyzed (Kiehl et al., 
2006; Kiehl et al., 2000; Lastres-Becker et al., 2008a; Satterfield et al., 2002). Since in C. elegans 
the polyQ repeats in all orthologous genes are not conserved, one could assume that much 
shorter repeat expansions than e.g. in the mouse may already give rise to a phenotype. 
However, the exact opposite seems to be true: Within the full-length context of a protein, 
much higher polyQ repeat numbers are required to be toxic (Khan et al., 2006; Teixeira-
Castro et al., 2011). Proteins with polyQ repeats are frequent in Drosophila (Alba et al., 2007), 
but these repeats are generally encoded by interrupted rather than pure CAG repeats and, 
therefore, more resistant to expansion (Alba et al., 2001). This could lead to the assumption 
that pure CAG repeats may behave unstable in Drosophila as observed in human SCA 
patients and mouse models (Boy et al., 2010; Kaytor et al., 1997; Lorenzetti et al., 2000).  
However, CAG repeats seem to be perfectly stable in Drosophila even within a challenging 
genomic context (Jackson et al., 2005) pointing to a specific protection mechanism against 
repeat expansion in Drosophila. 
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Caenorhabditis 
elegans 
Drosophila 
melanogaster 
Mus musculus 
knock-out 
SCA2: lethal (1) 
SCA3: viable (2) 
SCA2: lethal (3) SCA1/2/3/8: viable (4-9) 
overexpression of pure polyQ causes 
phenotype 
yes (10; 11) yes (12) yes (13; 14) 
truncated protein requires less  
repeats to induce phenotype 
yes (15) yes (16) yes (13) 
full-length protein causes phenotype 
yes (≥ 130 Q) (15; 
17) 
wt: no or mild 
exp: strong  
(3; 18-22) 
wt: no 
exp: mild to strong 
(23-26) 
instability of repeats  no (27) 
SCA1/3: yes (28-30) 
SCA2: no (24) 
repeat numbers causing phenotype ≥ 130 Q (15; 17) ≥30 Q (18) ≥ 30 Q (18; 24; 26) 
increasing repeat length intensifies 
phenotype 
yes (15; 17) yes (3; 18-22) yes (23-26) 
formation of aggregates yes (15; 17) yes (31) 
yes (33; 25) 
no (24; 32) 
late (30; 34) 
neurodegeneration/ neuronal loss  yes (18; 19; 35) 
wt: no 
exp: mild to strong 
(13; 23; 24; 36) 
switching-off led to reversal  
of symptom 
 yes (31) yes (30; 37) 
transgene leads to reduced lifespan yes (17) yes (31) yes (25) 
References: (1) Kiehl et al., 2000; (2) Rodrigues et al., 2007; (3) Satterfield et al., 2002; (4) Matilla et al., 
1998; (5) Kiehl et al., 2006; (6) Lastres-Becker et al., 2008a; (7) Schmitt et al., 2007 ; (8) Switonski et al., 
2011; (9) He et al., 2006; (10) Brignull et al., 2006a ; (11) Morley et al., 2002; (12) Marsh et al., 2000; (13) 
Ikeda et al., 1996; (14) Ordway et al., 1997; (15) Khan et al., 2006;  (16) Lu and Vogel, 2009; (17) Teixeira-
Castro et al., 2011); (18) Fernandez-Funez et al., 2000; (19) Al-Ramahi et al., 2007; (20) Warrick et al., 
1998; (21) Warrick et al., 2005; (22) Moseley et al., 2006; (23) Burright et al., 1995; (24) Huynh et al., 2000; 
(25) Bichelmeier et al., 2007; (26) Friedman et al., 2007; (27) Jackson et al., 2005; (28) Kaytor et al., 1997; 
(29) Lorenzetti et al., 2000; (30) Boy et al., 2009; (31) Latouche et al., 2007; (32) Silva-Fernandes et al., 
2010; (33) Cummings et al., 1999b ; (34) Watase et al., 2008; (35) Lessing and Bonini, 2008; (36) Aguiar et 
al., 2006; (37) Zu et al., 2004  
Table 2. Exemplary phenotypical features of human SCA patients compared among model 
organisms. For clearness, only examples for the respective phenotypic features are listed. 
The table is not intended to be exhaustive. (wt, normal repeat; exp, expanded repeat). 
5. Conclusion 
Multiple successful attempts generating transgenic animal models for SCA were performed 
in different species. While each model organism has its own advantages and disadvantages, 
all animal models contributed to the knowledge about the pathogenesis of SCA. The 
transparency of C.elegans together with the simplicity to generate transgenic models as well 
as the option to study neurodegeneration even macroscopically by targeting the gene of 
interest to the Drosophila eye make smaller organisms like the worm or the fly especially 
suitable for the screening of compounds or genetic modifiers. Since many pathologic 
mechanisms in SCA are conserved in these models, there is a high probability that results 
obtained in worms and flies can be translated to mammals. Although unsuitable for large-
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scale (genetic and compound) screening approaches, mouse models are the ideal tools for 
verification of screening results in mammals. Viral injections now even allow a 
comparatively rapid analysis without the need of breeding or even generating transgenic 
mice. Especially to answer questions which require brain structures closer to humans or for 
analyses of ataxic movement or even emotional phenotypes, mammalian models are 
required. Taken together, model organisms are indispensable tools for the analysis of 
pathogenic mechanisms important for SCA in vivo. 
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